Compare Natco Pharma with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs AJANTA PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA AJANTA PHARMA NATCO PHARMA/
AJANTA PHARMA
 
P/E (TTM) x 16.0 22.5 71.1% View Chart
P/BV x 3.1 3.9 81.0% View Chart
Dividend Yield % 1.1 0.9 118.2%  

Financials

 NATCO PHARMA   AJANTA PHARMA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-19
AJANTA PHARMA
Mar-19
NATCO PHARMA/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs8491,422 59.7%   
Low Rs557898 62.1%   
Sales per share (Unadj.) Rs573.8233.5 245.7%  
Earnings per share (Unadj.) Rs176.044.0 400.3%  
Cash flow per share (Unadj.) Rs198.252.2 380.0%  
Dividends per share (Unadj.) Rs6.259.00 69.4%  
Dividend yield (eoy) %0.90.8 114.6%  
Book value per share (Unadj.) Rs842.7255.1 330.4%  
Shares outstanding (eoy) m36.5088.02 41.5%   
Bonus/Rights/Conversions BBBB-  
Price / Sales ratio x1.25.0 24.7%   
Avg P/E ratio x4.026.4 15.1%  
P/CF ratio (eoy) x3.522.2 16.0%  
Price / Book Value ratio x0.84.5 18.3%  
Dividend payout %3.620.5 17.3%   
Avg Mkt Cap Rs m25,660102,081 25.1%   
No. of employees `0005.06.8 72.9%   
Total wages/salary Rs m3,5594,307 82.6%   
Avg. sales/employee Rs Th4,225.33,022.6 139.8%   
Avg. wages/employee Rs Th718.0633.4 113.4%   
Avg. net profit/employee Rs Th1,295.9569.1 227.7%   
INCOME DATA
Net Sales Rs m20,94520,554 101.9%  
Other income Rs m1,302211 617.6%   
Total revenues Rs m22,24720,765 107.1%   
Gross profit Rs m7,9485,664 140.3%  
Depreciation Rs m810721 112.4%   
Interest Rs m19312 1,663.8%   
Profit before tax Rs m8,2475,143 160.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,8231,273 143.2%   
Profit after tax Rs m6,4243,870 166.0%  
Gross profit margin %37.927.6 137.7%  
Effective tax rate %22.124.8 89.3%   
Net profit margin %30.718.8 162.9%  
BALANCE SHEET DATA
Current assets Rs m23,47211,812 198.7%   
Current liabilities Rs m7,2873,776 193.0%   
Net working cap to sales %77.339.1 197.6%  
Current ratio x3.23.1 103.0%  
Inventory Days Days9277 119.1%  
Debtors Days Days8882 108.1%  
Net fixed assets Rs m18,64814,398 129.5%   
Share capital Rs m365175 208.1%   
"Free" reserves Rs m34,52522,277 155.0%   
Net worth Rs m30,76022,452 137.0%   
Long term debt Rs m07 0.0%   
Total assets Rs m43,03126,962 159.6%  
Interest coverage x43.7444.3 9.8%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.50.8 63.8%   
Return on assets %15.414.4 106.8%  
Return on equity %20.917.2 121.2%  
Return on capital %27.423.0 119.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m11,53610,682 108.0%   
Fx outflow Rs m2,9392,102 139.8%   
Net fx Rs m8,5978,580 100.2%   
CASH FLOW
From Operations Rs m6,6883,748 178.5%  
From Investments Rs m-6,122-2,228 274.8%  
From Financial Activity Rs m-509-1,475 34.5%  
Net Cashflow Rs m6645 146.0%  

Share Holding

Indian Promoters % 52.0 73.8 70.5%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 1.6 505.8%  
FIIs % 16.6 7.6 218.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 17.0 152.9%  
Shareholders   25,395 20,968 121.1%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   NOVARTIS  TORRENT PHARMA  STRIDES PHARMA SCIENCE  STERLING BIOTECH  ABBOTT INDIA  

Compare NATCO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 21 Points Higher; Banking and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended their day marginally higher.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (2QFY20); Net Profit Down 7.2% (Quarterly Result Update)

Nov 8, 2019 | Updated on Nov 8, 2019

For the quarter ended September 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 7.2% YoY). Sales on the other hand came in at Rs 6 bn (up 18.1% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Ditch the Risky Fixed Deposits for Safer 'Bluechip Deposits'(Profit Hunter)

Oct 30, 2019

Most people think stocks are riskier than fixed deposits and bonds. The last quarter century proves otherwise.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Nov 11, 2019 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS